The purpose of this file is to contract centrally the supply of olanzapine (DOE), oral aripiprazole (DOE), parenteral vinorelbine (DOE) and budesonide (DOE) / formoterol (DOE) for all service organizations in Osakidetza and health centers privately owned and not for profit, located in the Autonomous Community of Euskadi, within the framework provided for in article 30 of Law 8/1997, of June 26, on Health Organization of Euskadi, which sign an agreement of link with Osakidetza / Basque Health Service.
With this contracting file whose conditions are established in this document, it is intended to cover the use of the drugs included in the file to meet the clinical needs of Osakidetza patients and related centers that are summarized in the file's report
Supply of OLANZAPINA (DOE) medicines, for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided for in article 30 of Law 8 / 1997, of June 26, of the Health Organization of Euskadi, which sign a bonding agreement with Osakidetza / Basque Health Service.
LOT ONE - OLANZAPINE (DOE) ORAL OF 2,5 MG, 5 MG, 7,5 MG AND 10 MG conditioned in stamped blister in which each tablet / capsule is properly identified
Active substance: OLANZAPINA (DOE)
Amount of active substance: 2.5 mg, 5 mg, 7.5 mg and 10 mg
Pharmaceutical form: tablets / capsules and orodispersible tablets
Packaging conditions: unit dose
Maximum unit price: 0.050 euros / tablet or 2.5 mg capsule
(Taxes not included) € 0,100 / tablet or 5 mg capsule
€ 0,150 / tablet or capsule of 7.5 mg
€ 0.160 / tablet or 10 mg capsule
€ 0,110 / 5 mg orodispersible tablet
€ 0,170 / 10 mg orodispersible tablet
N
(First year of contract) 9,000 tablets or 5 mg capsules
2,500 tablets or capsules of 7.5 mg
11,000 tablets or 10 mg capsules
40,000 orodispersible tablets of 5 mg
70,000 10 mg orodispersible tablets
Maximum estimated budget: 20,135.00 euros
(First year of contract)
Supply of OLANZAPINA (DOE) medicines, for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided for in article 30 of Law 8 / 1997, of June 26, of the Health Organization of Euskadi, which sign a bonding agreement with Osakidetza / Basque Health Service.
LOT TWO - ORLANZAPINE (DOE) ORAL OF 15 MG AND 20 MG conditioned in stamped blister in which each tablet is properly identified
Active substance: OLANZAPINA (DOE)
Amount of active substance: 15 mg and 20 mg
Pharmaceutical form: orodispersible tablets
Packaging conditions: unit dose
Maximum unit price: € 0.290 / 15 mg orodispersible tablet
(Taxes not included) 0.350 euros / 20 mg orodispersible tablet
N
(First year of contract) 15,000 20 mg orodispersible tablets
Maximum estimated budget: 9,020.00 euros
(First year of contract)
Supply of OLANZAPINA (DOE) medicines, for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided for in article 30 of Law 8 / 1997, of June 26, of the Health Organization of Euskadi, which sign a bonding agreement with Osakidetza / Basque Health Service.
LOT THREE - PARENTERAL OLANZAPINA (DOE)
Active substance: OLANZAPINA (DOE)
Amount of active substance: 10 mg, 210 mg, 300 mg and 405 mg
Pharmaceutical form: vial
Packaging conditions: unit dose
Maximum unit price: 138,066 euros / 210 mg vial
(Taxes not included) 207,200 euros / 300 mg vial
266,271 euros / vial of 405 mg
3,010 euros / 10 mg vial
N
(First year of contract) 800 vials of 300 mg
750 vials of 405 mg
900 vials of 10 mg
Maximum estimated budget: 395,785.45 euros
(First year of contract)
Supply of ARIPIPRAZOL (DOE) medicines for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided in article 30 of Law 8/1997 , of June 26, of Health Organization of Euskadi, that sign an agreement to link with Osakidetza / Basque Health Service.
LOT FOUR - ARIPIPRAZOL (DOE) ORAL COMPRESSED packaged in stamped blister in which each tablet is properly identified
Active substance: ARIPIPRAZOL (DOE)
Amount of active substance: 5mg, 10mg and 15mg
Pharmaceutical form: orodispersible tablets and tablets
Packaging conditions: unit dose
Maximum unit price: € 0,120 / 5 mg tablet
(Taxes not included) 0.240 euros / 10 mg tablet
€ 0.360 / 15 mg tablet
€ 0.400 / 10 mg orodispersible tablet
0.640 euros / 15 mg orodispersible tablet
N
(First year of contract) 6,000 10 mg tablets
7,000 15 mg tablets
13,000 10 mg orodispersible tablets
19,000 orodispersible tablets of 15 mg
Maximum estimated budget: 23,000.00 euros
(First year of contract)
Supply of VINORELBINA medicines (DOE) for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided for in article 30 of Law 8/1997 , of June 26, of Health Organization of Euskadi, that sign an agreement to link with Osakidetza / Basque Health Service.
LOT FIVE - VINORELBINA (DOE) PARENTERAL
Active ingredient: VINORELBINA (DOE)
Amount of active substance: 10 mg and / or 50 mg
Pharmaceutical form: vial
Packaging conditions: unit dose
Maximum unit price: 0.270 euros / mg
(Taxes not included)
N
(First year of contract)
Maximum estimated budget: € 24,300.00
(First year of contract)
Supply of FORMOTEROL ASSOCIATION (DOE) / BUDESONIDA (DOE) medicines for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided for in Article 30 of Law 8/1997, of June 26, on the Health Organization of Euskadi, which sign a linkage agreement with Osakidetza / Basque Health Service.
LOT SIX - FORMOTEROL ASSOCIATION (DOE) / BUDESONIDA (DOE) inhalation powder
Active substance: BUDESONIDA (DOE) AND FORMOTEROL (DOE)
Amount of active substance: 160 mcg / 4.5 mcg and 320 mcg / 9 mcg
Pharmaceutical form: inhalation powder
Packaging conditions: unit dose preferably
Maximum unit price: 0.99 euros / 160 mcg / 4.5 mcg inhaler, 120 doses
(Taxes not included) € 0.99 / 320 mcg / 9 mcg inhaler, 60 doses
N
(First year of contract) 250 inhalers of 320 mcg / 9 mcg, 60 doses
Maximum estimated budget: 2,821.50 euros
(First year of contract)
Supply of FORMOTEROL ASSOCIATION (DOE) / BUDESONIDA (DOE) medicines for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided for in Article 30 of Law 8/1997, of June 26, on the Health Organization of Euskadi, which sign a linkage agreement with Osakidetza / Basque Health Service.
LOT SEVEN - FORMOTEROL ASSOCIATION (DOE) / BUDESONIDA (DOE) suspension for inhalation in a pressure container
Active substance: BUDESONIDA (DOE) AND FORMOTEROL (DOE)
Amount of active substance: 160 mcg / 4.5 mcg and 320 mcg / 9 mcg
Pharmaceutical form: suspension for inhalation in pressurized container
Packaging conditions: unit dose preferably
Maximum unit price: 0.99 euros / 160 mcg / 4.5 mcg inhaler, 120 doses
(Taxes not included)
N
(First year of contract)
Maximum estimated budget: 198.00 euros
(First year of contract)